WWM
RPRX icon

Whalen Wealth Management’s Royalty Pharma RPRX Stock Holding History

Whalen Wealth Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-17,419
Closed -$628K – 256
2025
Q2 		$628K Buy
+17,419
New +$577K 0.39% 75

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Whalen Wealth Management's RPRX Position: Q3 2025 in Review

Whalen Wealth Management sold out of Royalty Pharma (RPRX) in Q3 2025, closing a stake of 17,419 shares — an estimated $628K sold.

Whalen Wealth Management first reported a position in RPRX in Q2 2025 and held it in 1 quarter. The position peaked at $628K in Q2 2025. 487 funds tracked by Wall St. Rank hold RPRX as of Q3 2025.

  • Whalen Wealth Management reported no remaining Royalty Pharma position as of Q3 2025 after selling out during the quarter.
  • Whalen Wealth Management sold 17,419 Royalty Pharma shares in Q3 2025, an estimated $628K.
  • Whalen Wealth Management first reported a position in Royalty Pharma in Q2 2025 and held it in 1 quarter.
  • Whalen Wealth Management's Royalty Pharma position peaked at $628K in Q2 2025.
  • 487 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2025.

Based on Whalen Wealth Management's 13F filing for Q3 2025, filed 9 Oct 2025.